Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Med LifeLTS:0RO5 80 Forward PE Ratio is 32.04 as of Jul. 23, 2026. GuruFocus rates LTS:0RO5 with a GF Score™ of 80/100 and a GF Value™ of lei7.35 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 313 Healthcare Providers & Services companies, Med Life ranks worse than 77.32% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Med Life Forward PE Ratio Related Terms
Med Life Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Med Life's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Med Life Forward PE Ratio Chart
Med Life Annual Data
Trend
2024-12
Forward PE Ratio
9.28
Med Life Quarterly Data
2024-12
2025-03
2025-06
2025-09
2026-03
Forward PE Ratio
9.28
7.86
11.60
6.96
20.20
LTS:0RO5 vs HCA, THC, DVA: Forward PE Ratio Comparison
For the Medical Care Facilities subindustry, Med Life's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Med Life Forward PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Med Life's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Med Life's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Med Life (LTS:0RO5) has a Forward PE Ratio of 32.04 as of Jul. 23, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Med Life and its competitors. According to the industry distribution chart, Med Life ranks #242 out of 313 companies in the Healthcare Providers & Services industry, placing it in the top 77.3%.
Is Med Life's Forward PE Ratio too high?
Med Life's current Forward PE Ratio is 32.04. The Healthcare Providers & Services industry median Forward PE Ratio is 18.42. Med Life's value of 32.04 is 73.9% above this industry median. Based on the distribution chart, Med Life ranks #242 out of 313 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Med Life has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Med Life's Forward PE Ratio compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Med Life ranks #242 out of 313 companies for Forward PE Ratio. This places Med Life in the lower half of its industry. The industry median Forward PE Ratio is 18.42. Med Life's value of 32.04 is 73.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Healthcare Providers & Services company?
The median Forward PE Ratio among Healthcare Providers & Services companies is 18.42, based on 313 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Med Life's current Forward PE Ratio of 32.04 is 73.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Med Life and its competitors. For the Healthcare Providers & Services industry, the median Forward PE Ratio is 18.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Med Life's current Forward PE Ratio is 32.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Med Life stock overvalued right now?
Based on GuruFocus' analysis, Med Life (LTS:0RO5) is currently considered Significantly Overvalued. The stock's GF Value™ is lei7.35, compared to a current price of lei11.38 — trading 54.8% above its estimated fair value. The current Forward PE Ratio is 32.04 and 73.9% above the Healthcare Providers & Services industry median of 18.42. Med Life's overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Med Life (LTS:0RO5), the current Forward PE Ratio is 32.04 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Med Life (LTS:0RO5) Overvalued in 2026?
Based on GuruFocus' analysis, Med Life stock appears to be overvalued.
The current stock price of lei11.38 is trading 54.8% above its estimated GF Value™ of lei7.35.
GuruFocus considers Med Life to be Significantly Overvalued.
Key valuation signals for LTS:0RO5:
Forward PE Ratio: 32.04
GF Value™: lei7.35 vs. price of lei11.38 (54.8% above fair value)
Industry Position: 73.9% above the Healthcare Providers & Services median (#242 of 313)
No single metric tells the full story. See the LTS:0RO5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Med Life SA is a healthcare provider in Romania. The Company's activity resides in the performance of healthcare services activities through medical centres with national coverage. It is engaged in the provision of rendering of medical services, rental of medical facilities and acquisition of materials and commodities. The company provides medical service through Hyper clinics in Arad, Bucharest, Braila, Brasov, Cluj, Constanta, Craiova, Galati, Iasi, Oradea, Ploiesti, Sibiu and Timisoara; Clinics, hospitals located in Bucharest, Arad, Sibiu, Brasov, Cluj and Ploiesti, Laboratories, Pharmacies and Dental Clinics.
80GF Score
Get the complete analysis for LTS:0RO5
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RO5 has been successfully added to your 
